We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Industry Insights

Next-generation Sequencing Advancements in the Diagnostic Lab
Industry Insight

Agilent are working to increase the utility of NGS in the diagnostics field and in personalized medicine. We recently spoke with Ronda Allen, Head of R&D at Agilent, to learn more about two of Agilent's newest products in this space, the Cancer All-in-one (AIO) panels, and the Magnis NGS Library Prep System.

Read More

Fuelling Innovation in UK Life Sciences
Industry Insight

We spoke to Daniel Rooke, Head of Operations and Legal at Start Codon, to learn more about the company and how they can help early stage healthcare and life science businesses in the UK to get off the ground.

Read More

Easing the "Informatics Bottleneck" Burden in Next-generation Sequencing
Industry Insight

Technology Networks recently spoke with Rosengarten and Raymond Mercier, VP and GM, Molecular Biology, Thermo Fisher Scientific, to learn more about how the co-marketing agreement between Thermo Fisher Scientific and Genialis will help ease the burden of the "informatics bottleneck" for research scientists.

Read More

Analyzing Sperm DNA Damage To Diagnose Male Infertility
Industry Insight

A recent collaborative study between Examen and the Lister Fertility Clinic in London used Examen’s COMET assay to measure sperm DNA damage in men with unexplained infertility. We spoke with Professor Sheena Lewis, CEO of Examen, to learn more about the study, the links between sperm DNA damage and infertility, and the value of adding this parameter to fertility testing.

Read More

Life Science Technology Megatrends Shaping Our Future
Industry Insight

Megatrends are overarching trends, ones that seed and embrace multiple market and technology developments. These trends already exist in our world today but are going to be even more important in the years to come. Here we highlight three technology megatrends that could be highly significant to our future.

Read More

Applying Precision Genomics in Biopharma Drug Development
Industry Insight

A recent collaboration between Onconova Therapeutics and Mission will utilize the Mission Bio TapestriⓇ Platform to conduct targeted single-cell DNA analysis for the study of Onconova's novel cancer therapy, Rigosertib. We spoke with Darrin Crisitello, CCO of Mission Bio, to learn more.

Read More

Cell Conversions Transformed From Black Box Guesswork to Systematic Discovery
Industry Insight

Predicting the reprogramming factors necessary to induce cell conversion has largely relied on trial and error, revealing the need for a more systematic approach. To learn about Mogrify's approach to achieving cell conversion through transdifferentiation, we interviewed Pierre-Louis Joffrin, Corporate Development Executive at Mogrify.

Read More

Technology Networks Explores the CRISPR Revolution – Coming Soon
Industry Insight

Through a series of exclusive interviews with world-renowned scientists and bioethicists, Technology Networks Explores the CRISPR Revolution will investigate the ground-breaking research taking place in the CRISPR space, CRISPR "controversies" and whether the CRISPR technology looks set to fulfil its promise of revolutionizing science.

Read More

10 Things to Note About Manufacturing Viral Vectors
Industry Insight

10 things to note about viral vector manufacturing, regarding the complexities and challenges, and the technology that will help drive cell and gene therapy forward. Here we share insights from Pall and Molmed representatives, who are leaders in the fields of bioprocessing and cell and gene therapy.

Read More

Harnessing the Power of Proteins To Unlock Cell and Gene Therapies
Industry Insight

We recently spoke with Paul Wotton, Ph.D., CEO at Obsidian Therapeutics, to gain his insights on the genetically engineered cell-therapy research area, and to learn how Obsidian Therapeutics' cytoDRiVE platform can increases the specificity and safety of such therapies.

Read More

 
Advertisement